NewAmsterdam Pharma N.V.

NAMS | NASDAQ

Price Alert Chart Builder DCF Calculator

$20.06

-$0.70 (-3.37%)

At close: Oct 30, 2026, 4:00 PM ET

$20.56

+$0.50 (+2.50%)

Pre-market: Nov 2, 2026, 7:02 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $2.35B

Enterprise Value $1.71B

Beta 0.10

Average Volume 1.34M

Shares Outstanding (Diluted) 123.37M

Shares Change YoY 9.65%

Institutional Ownership 98.88%

Exchange NASDAQ

ISIN NL00150012L7

Price Performance

Price Change 1M -17.5%

Price Change 3M -27.8%

Price Change 6M -29.4%

Price Change YTD -42.8%

Price Change 1Y -47.1%

Price Change 3Y 122.9%

Price Change 5Y 104.5%

1M CAGR (ann.) -10.8%

1Y CAGR (ann.) -44.0%

5Y CAGR (ann.) 15.4%

All-Time CAGR 11.8%

Valuation

PE Ratio -9.20

Forward PE N/A

PEG Ratio 0.27

Forward PEG -0.40

PS Ratio 329.32

Forward PS 15.30

PB Ratio 3.71

P/FCF Ratio -16.32

P/Adj. FCF Ratio -13.24

P/OCF Ratio -17.29

EV/Sales 240.32

EV/EBIT -6.71

EV/EBITDA -6.71

EV/FCF -11.91

Earnings Yield -10.9%

FCF Yield -6.1%

Adj. FCF Yield -7.5%

Financial Health

Net Cash $633.85M

Total Debt $82K

Cash & Short-Term Investments $633.85M

Total Assets $704.45M

Current Ratio 9.03

Quick Ratio 9.03

Debt / Equity Ratio 0.00

Debt / EBITDA -0.00

Debt / FCF -0.00

OCF / Debt -1,749.54

Interest Coverage 0.00

Altman Z-Score 17.34

Piotroski F-Score 1

Margins & Profitability

Gross Profit Margin 92.2%

Operating Profit Margin -3432.2%

EBITDA Margin -3579.7%

Net Profit Margin -3644.2%

FCF Margin -2018.3%

Adj. FCF Margin -2487.2%

SBC / Revenue 468.9%

SBC Impact (per share) -23.2%

Returns

Return on Assets -36.8%

Return on Equity -38.3%

Return on Invested Capital -38.7%

Return on Capital Employed -38.7%

Return on Tangible Assets -36.9%

Historical Growth (CAGR)

Revenue CAGR 3Y -30.7%

Revenue CAGR 5Y -36.0%

Revenue CAGR 10Y N/A

EPS CAGR 3Y 8.7%

EPS CAGR 5Y -15.4%

EPS CAGR 10Y N/A

FCF CAGR 3Y 11.4%

FCF CAGR 5Y -39.6%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 6

EPS Growth Next 3Y 54.3%

Revenue Growth Next 3Y 377.2%

Earnings Date Nov 4, 2026

EPS Estimate (next Q) -$0.49

EPS Growth Est (next Q) -18.9%

Revenue Est (next Q) $7.54M

Revenue Growth Est (next Q) 2066.7%

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $51.33

Price Target Upside 155.9%

Cash Flow

Operating Cash Flow $-143.46M

Free Cash Flow $-143.72M

Adj. Free Cash Flow $-177.11M

FCF Per Share -$1.16

OCF Per Share -$1.16

OCF/S Ratio -2014.6%

Income Statement

Revenue $7.12M

Gross Profit $6.56M

Operating Income $-244.41M

EBITDA $-254.88M

Net Income $-259.5M

EPS (Diluted) -$2.18

Revenue / Employee $71.21K

Profit / Employee $-2.6M

Employees 100